Activity of Oritavancin and Its Synergy with Other Antibiotics Against Infection In Vitro and In Vivo

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 2

PMID 34198513

Citations 2

Authors

Gaoyan Wang

Jia Tang

Jiajia Feng

Wenqi Dong

Xinyu Huo

Hao Lu

Chenchen Wang

Wenjia Lu

Xiangru Wang

Huanchun Chen

Chen Tan

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary disease caused by () spreads around the world, and this disease is extremely difficult to treat due to intrinsic and acquired resistance of the pathogen to many approved antibiotics. is regarded as one of the most drug-resistant mycobacteria, with very limited therapeutic options.

Methods: Whole-cell growth inhibition assays was performed to screen and identify novel inhibitors. The IC of the target compounds were tested against THP-1 cells was determined to calculate the selectivity index, and then time-kill kinetics assay was performed against . Subsequently, the synergy of oritavancin with other antibiotics was evaluated by using checkerboard method. Finally, in vivo efficacy was determined in an immunosuppressive murine model simulating infection.

Results: We have identified oritavancin as a potential agent against . Oritavancin exhibited time-concentration dependent bactericidal activity against and it also displayed synergy with clarithromycin, tigecycline, cefoxitin, moxifloxacin, and meropenem in vitro. Additionally, oritavancin had bactericidal effect on intracellular . Oritavancin significantly reduced bacterial load in lung when it was used alone or in combination with cefoxitin and meropenem.

Conclusions: Our in vitro and in vivo assay results indicated that oritavancin may be a viable treatment option against infection.

Citing Articles

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.

Calcagno A, Coppola N, Sarmati L, Tadolini M, Parrella R, Matteelli A Infection. 2024; 52(3):737-765.

PMID: 38329686 PMC: 11142973. DOI: 10.1007/s15010-024-02183-3.

The role of long-acting antibiotics in the clinical practice: a narrative review.

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M Infez Med. 2023; 31(4):449-465.

PMID: 38075413 PMC: 10705857. DOI: 10.53854/liim-3104-4.

References

Hamad B . The antibiotics market. Nat Rev Drug Discov. 2010; 9(9):675-6. DOI: 10.1038/nrd3267. View

Wu M, Aziz D, Dartois V, Dick T . NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018; 23(8):1502-1519. PMC: 6078814. DOI: 10.1016/j.drudis.2018.04.001. View

Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View

Egorova A, Jackson M, Gavrilyuk V, Makarov V . Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. Med Res Rev. 2021; 41(4):2350-2387. PMC: 8217127. DOI: 10.1002/med.21798. View

Chew K, Octavia S, Go J, Ng S, Tang Y, Soh P . In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens. J Antimicrob Chemother. 2020; 76(4):973-978. DOI: 10.1093/jac/dkaa520. View

Mukherjee D, Wu M, Teo J, Dick T . Vancomycin and Clarithromycin Show Synergy against . Antimicrob Agents Chemother. 2017; 61(12). PMC: 5700366. DOI: 10.1128/AAC.01298-17. View

Reynolds P . Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989; 8(11):943-50. DOI: 10.1007/BF01967563. View

Bryant J, Grogono D, Rodriguez-Rincon D, Everall I, Brown K, Moreno P . Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016; 354(6313):751-757. PMC: 5142603. DOI: 10.1126/science.aaf8156. View

Winthrop K, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M . Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010; 182(7):977-82. DOI: 10.1164/rccm.201003-0503OC. View

10.

Sarathy J, Ganapathy U, Zimmerman M, Dartois V, Gengenbacher M, Dick T . TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother. 2020; 64(4). PMC: 7179298. DOI: 10.1128/AAC.02404-19. View

11.

Lavollay M, Dubee V, Heym B, Herrmann J, Gaillard J, Gutmann L . In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2013; 20(5):O297-300. DOI: 10.1111/1469-0691.12405. View

12.

Johansen M, Herrmann J, Kremer L . Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020; 18(7):392-407. DOI: 10.1038/s41579-020-0331-1. View

13.

Lerat I, Cambau E, Roth Dit Bettoni R, Gaillard J, Jarlier V, Truffot C . In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis. 2013; 209(6):905-12. DOI: 10.1093/infdis/jit614. View

14.

Moore M, FRERICHS J . An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol. 1953; 20(2):133-69. DOI: 10.1038/jid.1953.18. View

15.

Baines S, OConnor R, Saxton K, Freeman J, Wilcox M . Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother. 2008; 62(5):1078-85. DOI: 10.1093/jac/dkn358. View

16.

Rubino C, Bhavnani S, Moeck G, Bellibas S, Ambrose P . Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015; 59(6):3365-72. PMC: 4432154. DOI: 10.1128/AAC.00176-15. View

17.

Boylan C, Campanale K, Iversen P, Phillips D, Zeckel M, Parr Jr T . Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003; 47(5):1700-6. PMC: 153305. DOI: 10.1128/AAC.47.5.1700-1706.2003. View

18.

Kwak N, Dalcolmo M, Daley C, Eather G, Gayoso R, Hasegawa N . pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019; 54(1). DOI: 10.1183/13993003.01991-2018. View

19.

Taylor J, Palmer S . Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant. 2006; 25(8):985-8. DOI: 10.1016/j.healun.2006.04.003. View

20.

Corey G, Kabler H, Mehra P, Gupta S, Overcash J, Porwal A . Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014; 370(23):2180-90. DOI: 10.1056/NEJMoa1310422. View